Aspire Real Estate Investors, Inc. focuses on investing, developing, remodeling and managing a portfolio of multi-family properties in metropolitan areas of the United States. The company is headquartered in Irvine, California.
136 articles
ASP Isotopes targets $300 million EBITDA by 2031 following its inaugural Capital Markets Day, driven by liquid helium, radiopharmacy, and stable isotope commercialization. The company also announced p
ASP Isotopes Inc. COO Robert Ainscow sold 8,438 shares at $4.292 per share under a Rule 10b5-1 plan to cover tax withholding obligations on vested restricted stock awards.
ASP Isotopes Inc. is exploring a nuclear fuel conversion pilot in Namibia via subsidiary QLE to strengthen global fuel-cycle capabilities. The project leverages Namibia's uranium production to transit
ASP Isotopes Inc. submitted a filing under Securities Act Rule 425 concerning prospectuses and communications related to ongoing business combination transactions.
ASP Isotopes Inc. plans to commence commercial helium production and expand stable isotope facilities, including Silicon-28 and Carbon-14, within six months. Initial shipments from its South African p
ASP Isotopes outlined a plan to commercialize helium, isotopes, and nuclear fuel projects within six months to drive revenue. Key initiatives include silicon-28, carbon-14, and ytterbium-176 productio
ASP Isotopes' subsidiary Tetra4 has begun commissioning its Phase 1 liquid helium plant in South Africa, targeting first commercial shipments by September 2026. The project is projected to generate ov
ENDRA Life Sciences announced that ASP Isotopes' partner, Tetra4, has initiated commissioning for the liquid helium plant at the Virginia Gas Project. This marks a significant operational milestone fo
ASP Isotopes Inc.'s subsidiary Renergen has commenced commissioning a liquid helium plant in South Africa to address global shortages. Commercial shipments are anticipated by September 2026, with Phas
ASP Isotopes subsidiary Quantum Leap Energy is evaluating a pilot fluorination facility in Namibia for nuclear fuel cycle technologies. While entering public environmental review, no final investment
ASP Isotopes Inc. announced its subsidiary Quantum Leap Energy is evaluating metal conversion opportunities in Namibia. An environmental assessment is underway for a proposed pilot-scale hydrofluorina
ASP Isotopes Inc. submitted a Form 8K filing on August 18, leading to a 3.98% decline in its common stock price as reported by Investing.com.
ASP Isotopes reported Q2 2026 earnings with revenue reaching US$5.1 million, though stock valuation remains strained due to high multiples and dilution despite narrowing losses.
ASP Isotopes reported a quarterly loss of $0.28 per share, missing analyst estimates by $0.11. Shares fell 0.2% to $4.27 following the release, while insiders sold over $2 million worth of stock.
ASP Isotopes Inc. reported quarterly revenue of $5.1 million and narrowed its net loss to $34.0 million following the acquisition of Renergen. The deal diversified the company into helium and LNG sect
ASP Isotopes targets commercial isotope deliveries by late 2026, launching helium production in Virginia and expanding radiopharmacy capabilities via acquisitions and cyclotron technology integration.
ASP Isotopes secured a five-year take-or-pay LNG contract with a South African food processor for its Virginia Gas Project. The agreement covers 10% of Phase 1 capacity at over $16 per GJ, with produc
ASP Isotopes Inc. is set to release Q2 2026 earnings on August 14th, with analysts forecasting a $0.17 per share loss and $4.47 million revenue.
ASP Isotopes Inc. filed a Form 8K on August 6 according to Investing.com, though the announcement provided no further details regarding the specific contents of the filing.
ASP Isotopes Inc.'s subsidiary Tetra4 secured a five-year take-or-pay contract to supply LNG from South Africa's Virginia Gas Project to a food processor, covering 10% of Phase 1 capacity at over $16/
ASP Isotopes' subsidiary Tetra4 secured a five-year LNG supply contract to a domestic food processor via the Virginia Gas Project in South Africa, targeting commercial operations in Q3 2026 at over $1
ASP Isotopes will host investor meetings at the Citi Natural Resources Conference on August 13, 2026, discussing proposed merger transactions involving ENDRA, Renergen, and Noble Africa.
ASP Isotopes Inc. will host investor meetings at Citi's 2026 Natural Resources Conference, showcasing isotope enrichment technologies for critical materials and announcing a proposed merger with ENDRA
ASP Isotopes forecasts $14 million revenue for its PET Labs division by 2026, while helium production and isotope enrichment facilities near commercial launch. Subsidiary Renergen expects $27 million
ASP Isotopes reported over 50% organic revenue growth for its PET Labs segment in H1 2026, while isotope facilities and Renergen projects approach key milestones ahead of Q2 financial results.
ASP Isotopes reported 50% organic revenue growth in PET Labs and near-commercial production of Silicon-28 and Ytterbium-176. The company highlighted helium production plans amid global shortages while
ASP Isotopes Inc. will present at the Canaccord Genuity Growth Conference on August 12, 2026, led by CCO Viktor Petkov. The press release also highlighted proposed merger transactions with ENDRA, Rene
ASP Isotopes announced a live webcast of its Chief Commercial Officer's presentation at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The session will detail proprietary sepa
ASP Isotopes Inc received a valuation score of 8.28 within the Pharmaceuticals industry, with a P/E ratio of -1.73 indicating significant volatility against recent market levels.
ASP Isotopes Inc reported a 279.45% revenue increase to $4.18 million and 18.57% net profit growth, maintaining stable financial status despite limited disclosure on operational efficiency within the
ChemBrief